Yao BB, Fredrick LM, Schnell G, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: an integrated analysis of phase 2/3 studies. Liver Int. 2020. doi:10.1111/liv.14535.
Yattoo GN. Treatment of chronic hepatitis C with ledipasvir/sofosbuvir combination during pregnancy [Abstract]. Hepatol Int. 2018;12(Suppl. 2):S292-S293.
Yeung LT, To T, King SM, Roberts EA. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat. 2007;14:797-805.
Yoneda M, Saito S, Ikeda T, et al. Hepatitis C virus directly associates with insulin resistance independent of the visceral fat area in nonobese and nondiabetic patients. J Viral Hepat. 2007;14(9):600-607.
Yoshida EM, Kwo P, Agarwal K, et al. Persistence of virologic response after liver transplant in hepatitis C patients treated with ledipasvir/sofosbuvir plus ribavirin pretransplant. Ann Hepatol. 2017;16(3):375-381.
Younossi ZM, Stepanova M, Afdhal NH, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63(2):337-345.
Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment. Pharmacol. Ther. 2015;41(6):544-563.
Younossi ZM, Stepanova M, Sulkowski MS, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis. 2015;212(3):367-377.
Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology. 2015;61(5):1471-1478.
Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol. 2016;111(6):808-816.
Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology. 2014;59(6):2161-2169.
Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016;65(1):33-39.
Younossi ZM, Stepanova M, Jacobson I. Not achieving sustained viral eradication of hepatitis C virus after treatment leads to worsening of patient-reported outcomes. Clin Infect Dis. 2019:pii: ciz243. doi:10.1093/cid/ciz243.
Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014;12(8):1349-1359.
Younossi ZM, Zheng L, Stepanova M, Venkatesan C, Mir HM. Moderate, excessive or heavy alcohol consumption: each is significantly associated with increased mortality in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2013;37(7):703-709.
Zahnd C, Salazar-Vizcaya LP, Dufour JF, et al. Impact of deferring HCV treatment on liver-related events in HIV+ patients. In: Conference on Retroviruses and Opportunistic Infections (CROI) February 23-26. Conference on Retroviruses and Opportunistic Infections (CROI) February 23-26. Seattle, WA; 2015.
Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol. 1998;28(1):27-33.